Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 52Carcinoma, Renal Cell 47Neoplasm Metastasis 24Neoplasms 18Kidney Neoplasms 18Neuroendocrine Tumors 17Carcinoma, Non-Small-Cell Lung 13Tuberous Sclerosis 12Stomach Neoplasms 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Recurrence 10Prostatic Neoplasms 10Lymphoma 10Hodgkin Disease 10Glioblastoma 10Colorectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Brain Neoplasms 9Lymphoma, Follicular 8Lung Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma 8Waldenstrom Macroglobulinemia 7Triple Negative Breast Neoplasms 7Sarcoma 7Multiple Myeloma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Central Nervous System Neoplasms 7

Interventions

Magnetic Resonance Spectroscopy 4Iodine-131 4Sunitinib 3dabrafenib 2Trastuzumab 2Thyrotropin Alfa 2Thyroidectomy 2Surgical Procedures, Operative 2Gefitinib 2Fluorodeoxyglucose F18 2Bortezomib 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pralsetinib 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1delta 24-sterol reductase 1copanlisib 1cediranib 1aldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Cancer, Papillary × Everolimus × Clear all
NCT01164176 2014-12-02

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Yonsei University

Phase 2 Completed
40 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡